Company
Aurinia Pharmaceuticals
TSE:AUP
Aurinia is a late stage biopharmaceutical company focused on the development of its novel therapeutic immunomodulating drug candidate, voclosporin, for the treatment of lupus nephritis.
5 stories
Aurinia Pharmaceuticals posts 4Q revenue of US$29 million
The pharma company reported a net loss of US$14.6 million or $0.17 per share in the fourth quarter ended December 31, 2018
Archive
Aurinia Pharma and Bengal Energy are Spec Buy says Mackie
Aurinia Pharma and Bengal Energy are Spec Buy says Mackie
Aurinia Pharmaceuticals raises US$7mln for lupus drug development
The funds allow Aurinia to prepare for Phase 3 drug trials.